RESUMEN
Regional and national legislation mandates the disclosure of "priority" allergens when present as an ingredient in foods, but this does not extend to the unintended presence of allergens due to shared production facilities. This has resulted in a proliferation of precautionary allergen ("may contain") labels (PAL) that are frequently ignored by food-allergic consumers. Attempts have been made to improve allergen risk management to better inform the use of PAL, but a lack of consensus has led to variety of regulatory approaches and nonuniformity in the use of PAL by food businesses. One potential solution would be to establish internationally agreed "reference doses," below which no PAL would be needed. However, if reference doses are to be used to inform the need for PAL, then it is essential to characterize the hazard associated with these low-level exposures. For peanut, there are now published data relating to over 3000 double-blind, placebo-controlled challenges in allergic individuals, but a similar level of evidence is lacking for other priority allergens. We present the results of a rapid evidence assessment and meta-analysis for the risk of anaphylaxis to a low-level allergen exposure for priority allergens. On the basis of this analysis, we propose that peanut can and should be considered an exemplar allergen for the hazard characterization at a low-level allergen exposure.
Asunto(s)
Anafilaxia , Hipersensibilidad a los Alimentos , Alérgenos , Arachis , Hipersensibilidad a los Alimentos/diagnóstico , Etiquetado de Alimentos , Humanos , Ensayos Clínicos Controlados Aleatorios como Asunto , Medición de RiesgoAsunto(s)
Alérgenos/efectos adversos , Relación Dosis-Respuesta Inmunológica , Hipersensibilidad a los Alimentos/etiología , Adolescente , Alérgenos/administración & dosificación , Alérgenos/inmunología , Niño , Preescolar , Corylus/inmunología , Método Doble Ciego , Hipersensibilidad al Huevo/etiología , Hipersensibilidad al Huevo/inmunología , Femenino , Hipersensibilidad a los Alimentos/inmunología , Humanos , Lactante , Almacenamiento y Recuperación de la Información , Masculino , Hipersensibilidad a la Leche/etiología , Hipersensibilidad a la Leche/inmunología , Hipersensibilidad a la Nuez/etiología , Hipersensibilidad a la Nuez/inmunología , Hipersensibilidad al Cacahuete/etiología , Hipersensibilidad al Cacahuete/inmunología , Placebos , Gestión de RiesgosRESUMEN
BACKGROUND: It is challenging to define likely food allergy (FA) in large populations which limited the number of large studies regarding risk factors for FA. OBJECTIVE: We studied the prevalence and characteristics of self-reported FA (s-rFA) in the large, population-based Dutch Lifelines cohort and identified associated risk factors. METHODS: Likely food allergic cases (LikelyFA) were classified based on questionnaire reported characteristics consistent with FA. Subjects with atypical characteristics were classified as Indeterminate. We investigated 13 potential risk factors for LikelyFA such as birth mode and living on a farm and addressed health-related quality of life (H-RQOL). RESULTS: Of the 78, 890 subjects, 12.1% had s-rFA of which 4.0% and 8.1% were classified as LikelyFA and Indeterminate, respectively. Younger age, female sex, asthma, eczema and nasal allergy increased the risk of LikelyFA (p-value range <1.00*10-250-1.29*10-7). Living in a small city/large village or suburb during childhood was associated with a higher risk of LikelyFA than living on a farm (p-value = 7.81*10-4 and p = 4.84*10-4, respectively). Subjects classified as Indeterminate more often reported depression and burn-out compared to those without FA (p-value = 1.46*10-4 and p = 8.39*10-13, respectively). No association was found with ethnicity, (duration of) breastfeeding, birth mode and reported eating disorder. Mental and physical component scores measuring H-RQOL were lower in both those classified as LikelyFA and Indeterminate compared to those without FA. CONCLUSION: The prevalence of s-rFA among adults is considerable and one-third reports characteristics consistent with LikelyFA. Living on a farm decreased the risk of LikelyFA. The association of poorer H-RQOL as well as depression and burn-out with questionable self-perceived FA is striking and a priority for future study.
Asunto(s)
Hipersensibilidad a los Alimentos/epidemiología , Adulto , Alérgenos , Asma/epidemiología , Estudios de Cohortes , Eccema/epidemiología , Femenino , Alimentos , Humanos , Masculino , Persona de Mediana Edad , Países Bajos/epidemiología , Prevalencia , Calidad de Vida , Rinitis Alérgica Estacional/epidemiología , Factores de Riesgo , Encuestas y CuestionariosRESUMEN
BACKGROUND: Food allergies are a significant public health issue, and the only effective management option currently available is strict avoidance of all foods containing the allergen. In view of the practical impossibility of limiting risks to zero, quantitative allergen risk assessment and management strategies are needed. OBJECTIVE: We sought to develop appropriate methods for informing population-based risk assessments and risk management programs to benefit all stakeholders but particularly patients with food allergy. METHODS: Individual thresholds for food allergens (maximum tolerable doses and minimum eliciting doses) can ideally be established through double-blind, placebo-controlled food challenges. If double-blind, placebo-controlled food challenge data are not available, data from widely used open food challenges using predefined objective criteria can also provide useful data regarding minimum eliciting doses. For more than 20 years, the Netherlands Organisation for Applied Scientific Research and the Food Allergy Research and Resource Program at the University of Nebraska-Lincoln have been collecting individual maximum tolerable doses and minimum eliciting doses that produce objective symptoms from published and unpublished clinical data to better refine knowledge regarding the sensitivity of the population to food allergens. RESULTS: In this article we provide in-depth insights into the methodology applied by the Netherlands Organisation for Applied Scientific Research and Food Allergy Research and Resource Program to derive individual maximum tolerable doses and minimum eliciting doses for objective symptoms from clinical food challenge data. More than 90 examples for determining individual allergic thresholds are presented. CONCLUSION: With the methodology presented in this article, we aim to stimulate harmonization and transparency in quantitative food allergen risk assessment and risk management programs, encouraging their wider adoption.
Asunto(s)
Hipersensibilidad a los Alimentos/diagnóstico , Inmunización/métodos , Grupos de Población , Administración Oral , Alérgenos/inmunología , Variación Biológica Individual , Preescolar , Toma de Decisiones Clínicas , Método Doble Ciego , Femenino , Alimentos , Humanos , Lactante , Masculino , Dosis Máxima Tolerada , Nivel sin Efectos Adversos Observados , Efecto Placebo , Medición de RiesgoRESUMEN
PURPOSE: Children with bronchopulmonary dysplasia often develop complications that affect them well into adult life. Very little is known about how this affects their quality of life, since no sensitive instrument is available to measure health-related quality of life in this population. In this study, a Dutch parent-proxy instrument was developed for this purpose. METHODS: A list of items was generated after literature search and interviews with both parents of patients and clinical experts. Clinically relevant items were selected with the clinical impact method and item analysis. Results of clinical tests to measure complications in children with bronchopulmonary dysplasia were correlated with these items to select the items that show construct validity. Cronbach's alpha was calculated to estimate internal consistency of the items in the final questionnaire. RESULTS: In total, 92 children and their parents and 7 clinicians participated. Of 130 identified items, 47 showed clinical relevance. Spirometry, the Child Behavior Checklist, mean arterial pressure, and body mass index were used to determine construct validity of 33 items. These items were structured within five domains: pulmonary complaints, school functioning, growth and nutrition, exercise and locomotion, emotional functioning and health care concerns. The questionnaire showed excellent internal consistency with Cronbach's alpha of 0.919. CONCLUSION: This study developed a disease-specific parent-proxy instrument to measure health-related quality of life in children with bronchopulmonary dysplasia aged 4-8 years old, the BPD-QoL. All included items show construct validity and internal consistency reliability. Future research should focus on further validation and analysis of responsiveness and reliability.
Asunto(s)
Displasia Broncopulmonar/psicología , Psicometría/métodos , Calidad de Vida/psicología , Niño , Preescolar , Femenino , Humanos , Masculino , Reproducibilidad de los Resultados , Encuestas y CuestionariosRESUMEN
BACKGROUND: Allergic sensitisation towards cashew nut often happens without a clear history of eating cashew nut. IgE cross-reactivity between cashew and pistachio nut is well described; however, the ability of cashew nut-specific IgE to cross-react to common tree nut species and other Anacardiaceae, like mango, pink peppercorn, or sumac is largely unknown. OBJECTIVES: Cashew nut allergic individuals may cross-react to foods that are phylogenetically related to cashew. We aimed to determine IgE cross-sensitisation and cross-reactivity profiles in cashew nut-sensitised subjects, towards botanically related proteins of other Anacardiaceae family members and related tree nut species. METHOD: Sera from children with a suspected cashew nut allergy (n = 56) were assessed for IgE sensitisation to common tree nuts, mango, pink peppercorn, and sumac using dot blot technique. Allergen cross-reactivity patterns between Anacardiaceae species were subsequently examined by SDS-PAGE and immunoblot inhibition, and IgE-reactive allergens were identified by LC-MS/MS. RESULTS: From the 56 subjects analysed, 36 were positive on dot blot for cashew nut (63%). Of these, 50% were mono-sensitised to cashew nuts, 19% were co-sensitised to Anacardiaceae species, and 31% were co-sensitised to tree nuts. Subjects co-sensitised to Anacardiaceae species displayed a different allergen recognition pattern than subjects sensitised to common tree nuts. In pink peppercorn, putative albumin- and legumin-type seed storage proteins were found to cross-react with serum of cashew nut-sensitised subjects in vitro. In addition, a putative luminal binding protein was identified, which, among others, may be involved in cross-reactivity between several Anacardiaceae species. CONCLUSIONS: Results demonstrate the in vitro presence of IgE cross-sensitisation in children towards multiple Anacardiaceae species. In this study, putative novel allergens were identified in cashew, pistachio, and pink peppercorn, which may pose factors that underlie the observed cross-sensitivity to these species. The clinical relevance of this widespread cross-sensitisation is unknown.
Asunto(s)
Alérgenos/inmunología , Reacciones Cruzadas/inmunología , Inmunoglobulina E/inmunología , Hipersensibilidad a la Nuez/inmunología , Nueces/efectos adversos , Adolescente , Especificidad de Anticuerpos/inmunología , Niño , Preescolar , Femenino , Humanos , Hipersensibilidad Inmediata/diagnóstico , Hipersensibilidad Inmediata/inmunología , Inmunización , Masculino , Hipersensibilidad a la Nuez/diagnósticoAsunto(s)
Anafilaxia/terapia , Desensibilización Inmunológica/métodos , Hipersensibilidad/terapia , Mordeduras y Picaduras de Insectos/terapia , Adulto , Alérgenos/inmunología , Anafilaxia/inmunología , Animales , Cálculo de Dosificación de Drogas , Femenino , Humanos , Hipersensibilidad/inmunología , Mordeduras y Picaduras de Insectos/inmunología , Masculino , Persona de Mediana Edad , Venenos de Avispas/inmunología , Avispas/inmunologíaRESUMEN
BACKGROUND: The allergy management support system (AMSS) was developed to assist general practitioners (GPs) to handle the increasing burden of allergic diseases and facilitates the diagnosis and management of allergy. The aim of this cluster-randomized controlled pilot study was to test the feasibility of this AMSS for primary care. METHODS: GPs received diagnostic and management recommendations generated by the AMSS in addition to sIgE-test results (intervention) or GPs received sIgE-test results only (control). The AMSS recommendations are based on the previously developed patient-completed AMSS questionnaire and sIgE-test results. The AMSS was considered feasible when > 70% of the AMSS recommendations were sent to the GP within ten working days of sIgE-testing. GPs completed a questionnaire on their diagnosis and management before (T1) and after (T2) receiving sIgE test results. Agreement and disagreement concerning diagnosis, medication and referrals between GPs and AMSS was investigated at T1 and T2. A total agreement score between GPs and AMSS was calculated. GPs in the intervention group completed a questionnaire to evaluate the utility of the AMSS. Semi-structured interviews were used to explore the motivation of GPs who did not include patients in this pilot study. RESULTS: Twenty-seven GPs included 101 patients. Forty-two patients (72%) completed the AMSS questionnaire in the intervention group. The majority of the AMSS recommendations (93%) were returned to the GP within 10 working days after sIgE-test results were known [mean (SD) 4.7 (4.0) working days]. GPs in the intervention group reported largely following the AMSS recommendations in 71% of cases. The total agreement scores concerning diagnosis were significantly higher (p < 0.001) in the intervention group than the control group [mean (SD); 0.9 (1.8) vs - 0.8 (1.0)]. The agreement concerning medication or referral between GPs and AMSS did not differ between the intervention and the control group. GPs in the intervention group were reasonably positive about the AMSS. Not enrolling patients was not caused by anticipated ineffectiveness of the AMSS. CONCLUSION: The AMSS can be considered to be feasible for primary care. GPs tend to follow the AMSS recommendations. The AMSS may contribute to the empowerment of GPs to better manage allergy patients in primary care.Trial registration ISRCTN ISRCTN36780877. Registered 23 November 2017 (retrospectively registered).
Asunto(s)
Alérgenos/inmunología , Arachis/efectos adversos , Inmunización , Hipersensibilidad al Cacahuete/inmunología , Alérgenos/administración & dosificación , Niño , Preescolar , Femenino , Humanos , Hipersensibilidad/diagnóstico , Hipersensibilidad/inmunología , Hipersensibilidad/terapia , Inmunización/métodos , Inmunoglobulina E/inmunología , Masculino , Hipersensibilidad al Cacahuete/diagnóstico , Hipersensibilidad al Cacahuete/terapia , Índice de Severidad de la EnfermedadAsunto(s)
Arachis/inmunología , Asma/genética , Asma/inmunología , Antígenos HLA/genética , Hipersensibilidad al Cacahuete/genética , Hipersensibilidad al Cacahuete/inmunología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Canadá , Niño , Preescolar , Femenino , Predisposición Genética a la Enfermedad/genética , Estudio de Asociación del Genoma Completo/métodos , Humanos , Lactante , Masculino , Persona de Mediana Edad , Polimorfismo de Nucleótido Simple/genética , Factores de Riesgo , Adulto JovenRESUMEN
BACKGROUND: Severe allergic reactions, including anaphylaxis, occur during oral food challenges (OFCs) and the first-line treatment of anaphylaxis is epinephrine. OBJECTIVE: To evaluate the percentage of anaphylactic reactions treated with epinephrine during OFCs and to identify associated factors for the administration of epinephrine. METHODS: Children who underwent an OFC with peanut, hazelnut, cow's milk, hen's egg, or cashew nut from 2005 through 2015 in the Netherlands were evaluated. Children with reactions meeting the criteria for anaphylaxis according to the European Academy of Allergy and Clinical Immunology guidelines for food allergy and anaphylaxis were included. Children with an anaphylactic reaction treated with vs without epinephrine were compared. Possible factors associated with the administration of epinephrine, such as age, sex, symptoms consistent with asthma, history of an allergic reaction to the tested allergen, and symptom types during the anaphylactic reaction, were evaluated using logistic regression analysis. RESULTS: Eighty-three children in clinical and research settings (43% boys; median age, 7 years; range, 1-17) who met the criteria for anaphylaxis were included in this study. Thirty-two of 83 children (39%) with anaphylaxis were treated with epinephrine. Respiratory symptoms during the OFC were treated significantly more often with epinephrine than gastrointestinal symptoms (P = .01). CONCLUSION: Only 39% of children with anaphylaxis, according to the guideline criteria, were treated with epinephrine during the OFC and most of these children had respiratory symptoms. There is need for an easy-to-use international guideline for the treatment of allergic symptoms during OFCs.
Asunto(s)
Anafilaxia/tratamiento farmacológico , Broncodilatadores/uso terapéutico , Epinefrina/uso terapéutico , Hipersensibilidad a los Alimentos/tratamiento farmacológico , Adolescente , Alérgenos , Anacardium/efectos adversos , Anafilaxia/diagnóstico , Animales , Arachis/efectos adversos , Pollos , Niño , Preescolar , Corylus/efectos adversos , Técnicas y Procedimientos Diagnósticos/efectos adversos , Huevos/efectos adversos , Femenino , Hipersensibilidad a los Alimentos/diagnóstico , Humanos , Lactante , Masculino , Leche/efectos adversos , Países BajosRESUMEN
BACKGROUND: Peanut allergy (PA) is a complex disease with both environmental and genetic risk factors. Previously, PA loci were identified in filaggrin (FLG) and HLA in candidate gene studies, and loci in HLA were identified in a genome-wide association study and meta-analysis. OBJECTIVE: We sought to investigate genetic susceptibility to PA. METHODS: Eight hundred fifty cases and 926 hyper-control subjects and more than 7.8 million genotyped and imputed single nucleotide polymorphisms (SNPs) were analyzed in a genome-wide association study to identify susceptibility variants for PA in the Canadian population. A meta-analysis of 2 phenotypes (PA and food allergy) was conducted by using 7 studies from the Canadian, American (nâ¯=â¯2), Australian, German, and Dutch (nâ¯=â¯2) populations. RESULTS: An SNP near integrin α6 (ITGA6) reached genome-wide significance with PA (Pâ¯=â¯1.80â¯×â¯10-8), whereas SNPs associated with Src kinase-associated phosphoprotein 1 (SKAP1), matrix metallopeptidase 12 (MMP12)/MMP13, catenin α3 (CTNNA3), rho GTPase-activating protein 24 (ARHGAP24), angiopoietin 4 (ANGPT4), chromosome 11 open reading frame (C11orf30/EMSY), and exocyst complex component 4 (EXOC4) reached a threshold suggestive of association (Pâ¯≤â¯1.49â¯×â¯10-6). In the meta-analysis of PA, loci in or near ITGA6, ANGPT4, MMP12/MMP13, C11orf30, and EXOC4 were significant (Pâ¯≤â¯1.49â¯×â¯10-6). When a phenotype of any food allergy was used for meta-analysis, the C11orf30 locus reached genome-wide significance (Pâ¯=â¯7.50â¯×â¯10-11), whereas SNPs associated with ITGA6, ANGPT4, MMP12/MMP13, and EXOC4 and additional C11orf30 SNPs were suggestive (Pâ¯≤â¯1.49â¯×â¯10-6). Functional annotation indicated that SKAP1 regulates expression of CBX1, which colocalizes with the EMSY protein coded by C11orf30. CONCLUSION: This study identifies multiple novel loci as risk factors for PA and food allergy and establishes C11orf30 as a risk locus for both PA and food allergy. Multiple genes (C11orf30/EMSY, SKAP1, and CTNNA3) identified by this study are involved in epigenetic regulation of gene expression.
Asunto(s)
Epigénesis Genética , Sitios Genéticos , Estudio de Asociación del Genoma Completo , Proteínas de Neoplasias/genética , Proteínas Nucleares/genética , Hipersensibilidad al Cacahuete/genética , Polimorfismo de Nucleótido Simple , Proteínas Represoras/genética , Homólogo de la Proteína Chromobox 5 , Femenino , Proteínas Filagrina , Humanos , Masculino , Hipersensibilidad al Cacahuete/epidemiología , Hipersensibilidad al Cacahuete/metabolismo , Fosfoproteínas/biosíntesis , Fosfoproteínas/genética , Factores de Riesgo , alfa Catenina/biosíntesis , alfa Catenina/genéticaRESUMEN
BACKGROUND: Patients with indolent systemic mastocytosis (ISM) are at risk for severe anaphylactic reactions to yellow jacket (YJ) stings while demonstration of sensitization can be challenging because specific IgE (sIgE) levels are regularly below 0.35 kUA/L. The implication of missing YJ allergy is illustrated by a case of fatal anaphylaxis. OBJECTIVE: To explore the natural course of YJ venom allergy and the diagnostic accuracy and therapeutic consequence of YJ venom sIgE in patients with ISM. METHODS: All patients with ISM seen from 1981 to 2015 (n = 243) were evaluated on the number of YJ stings, reaction severity, and sensitivity and specificity of YJ venom sIgE. YJ venom allergic patients without mastocytosis served as control (n = 313). RESULTS: A total of 153 patients with ISM were stung during adult life. The first systemic reaction was more often severe in patients with ISM than in patients without mastocytosis (69.9% vs 22.0%) and reactions recurred in 40 of 41 re-stung patients with ISM. ISM reactors showed lower YJ venom sIgE levels than nonmastocytosis reactors (0.61 vs 4.83 kUA/L; P < .001) and asymptomatic sensitization was exceedingly rare. In ISM the current clinical threshold of 0.35 kUA/L yields a sensitivity and specificity of 77.6% and 87.5%, respectively. The optimal diagnostic accuracy is achieved at 0.17 kUA/L (sensitivity, 83.6%; specificity, 85.0%). CONCLUSIONS: The high rate of severe reactions and the fatal case underscore the importance of adequate diagnostic sensitivity of sIgE in patients with ISM. The sensitivity of sIgE can be ameliorated by lowering the threshold to 0.17 kUA/L, retaining good specificity. We recommend sIgE screening in all patients with ISM and discussing immunotherapy when YJ venom sIgE exceeds 0.17 kUA/L.
Asunto(s)
Anafilaxia/diagnóstico , Desensibilización Inmunológica/métodos , Mordeduras y Picaduras de Insectos/diagnóstico , Mastocitosis Sistémica/diagnóstico , Adulto , Alérgenos/inmunología , Anafilaxia/epidemiología , Anafilaxia/terapia , Animales , Epinefrina/uso terapéutico , Resultado Fatal , Femenino , Humanos , Inmunoglobulina E/sangre , Mordeduras y Picaduras de Insectos/epidemiología , Masculino , Mastocitosis Sistémica/epidemiología , Mastocitosis Sistémica/terapia , Persona de Mediana Edad , Riesgo , Sensibilidad y Especificidad , Triptasas/sangre , Urticaria Pigmentosa , Venenos de Avispas/inmunología , AvispasAsunto(s)
Anacardium/inmunología , Técnicas de Apoyo para la Decisión , Hipersensibilidad a la Nuez/diagnóstico , Adolescente , Alérgenos/inmunología , Biomarcadores/sangre , Niño , Preescolar , Femenino , Humanos , Inmunoglobulina E/sangre , Modelos Logísticos , Masculino , Análisis Multivariante , Hipersensibilidad a la Nuez/inmunología , Oportunidad Relativa , Pruebas CutáneasAsunto(s)
Anafilaxia/sangre , Apolipoproteína B-100/sangre , Biomarcadores/sangre , Niño , Preescolar , Femenino , Humanos , MasculinoRESUMEN
BACKGROUND: Few studies with a limited number of patients have provided indications that cashew-allergic patients may experience severe allergic reactions to minimal amounts of cashew nut. The objectives of this multicentre study were to assess the clinical relevance of cashew nut sensitisation, to study the clinical reaction patterns in double-blind placebo-controlled food challenge tests and to establish the amount of cashew nuts that can elicit an allergic reaction. METHODS AND FINDINGS: A total of 179 children were included (median age 9.0 years; range 2-17 years) with cashew nut sensitisation and a clinical history of reactions to cashew nuts or unknown exposure. Sensitised children who could tolerate cashew nuts were excluded. The study included three clinical visits and a telephone consultation. During the first visit, the medical history was evaluated, physical examinations were conducted, blood samples were drawn and skin prick tests were performed. The children underwent a double-blind placebo-controlled food challenge test with cashew nut during the second and third visits. The study showed that 137 (76.5%) of the sensitised children suspected of allergy to cashew nut had a positive double-blind placebo-controlled food challenge test, with 46% (63) manifesting subjective symptoms to the lowest dose of 1 mg cashew nut protein and 11% (15) developing objective symptoms to the lowest dose. Children most frequently had gastro-intestinal symptoms, followed by oral allergy and skin symptoms. A total of 36% (49/137) of the children experienced an anaphylactic reaction and 6% (8/137) of the children were treated with epinephrine. CONCLUSION: This prospective study demonstrated a strikingly high percentage of clinical reactions to cashew nut in this third line population. Severe allergic reactions, including anaphylaxis requiring epinephrine, were observed. These reactions were to minimal amounts of cashew nut, demonstrated the high potency of this allergens. TRIAL REGISTRATION: www.ncbi.nlm.nih.gov/pubmed NTR3572.
Asunto(s)
Anacardium/efectos adversos , Hipersensibilidad a la Nuez/inmunología , Adolescente , Anafilaxia/tratamiento farmacológico , Niño , Preescolar , Desensibilización Inmunológica , Método Doble Ciego , Epinefrina/uso terapéutico , Femenino , Humanos , Masculino , Hipersensibilidad a la Nuez/tratamiento farmacológico , Pruebas CutáneasRESUMEN
BACKGROUND: Patient-reported outcome measures (PROMs) are measures of the outcome of treatment(s) reported directly by the patient or carer. There is increasing international policy interest in using these to assess the impact of clinical care. AIMS: To identify suitably validated PROMs for asthma and examine their potential for use in clinical settings. METHODS: We systematically searched MEDLINE, EMBASE and Web of Science databases from 1990 onwards to identify PROMs for asthma. These were critically appraised, then narratively synthesised. We also identified the generic PROMs commonly used alongside asthma-specific PROMs. RESULTS: We identified 68 PROMs for asthma, 13 of which were selected through screening as being adequately developed to warrant full-quality appraisal: 8 for adults, 4 for children and 1 for a child's caregiver. The PROMs found to be sufficiently well validated to offer promise for use in clinical settings were the Asthma Quality of Life Questionnaire (AQLQ) and mini-AQLQ for adults, and Pediatric Asthma Quality of Life Questionnaire for children. Rhinasthma was considered promising in simultaneously assessing the impact of asthma and rhinitis in those with coexistent disease. We identified 28 generic PROMs commonly used in conjunction with asthma-specific instruments. CONCLUSIONS: We identified asthma PROMs that offer the greatest potential for use in clinical settings. Further work is needed to assess whether these are fit-for-purpose for use in clinical practice with individual patients. In particular, there is a need to ensure these are validated for use in clinical settings, acceptable to patients, caregivers and clinicians, and yield meaningful outcomes.